## Analysis of Pancreatic Adenocarcinoma Characteristics ### Why CA 19-9 Is NOT Suitable for Screening **Key Point:** CA 19-9 has poor sensitivity and specificity for early-stage pancreatic cancer and is NOT recommended for screening asymptomatic populations. - Sensitivity for early disease: ~50–60% - Specificity: ~90%, but elevated in benign conditions (pancreatitis, cirrhosis, gastric cancer) - Role is limited to monitoring treatment response and detecting recurrence in known cases - No major guideline (NCCN, ESMO, ASCO) recommends CA 19-9 screening in asymptomatic individuals ### Correct Features of Pancreatic Cancer | Feature | Details | |---------|----------| | **Risk Factors** | Smoking (2–3× risk), chronic pancreatitis (50× risk), family history, diabetes, obesity | | **Head Tumors** | Present with painless obstructive jaundice due to CBD compression | | **KRAS Mutations** | Found in ~90% of pancreatic adenocarcinomas; early and frequent event | | **Screening** | No effective screening for asymptomatic population; high-risk individuals (hereditary cancer syndromes, familial pancreatitis) may undergo surveillance with EUS/MRI | **High-Yield:** The poor performance of CA 19-9 for early detection is a classic NEET PG trap — students often confuse its role as a prognostic/monitoring marker with a screening tool. **Clinical Pearl:** Painless jaundice in a 60-year-old with weight loss and elevated CA 19-9 is pancreatic cancer until proven otherwise — but CA 19-9 elevation alone does not warrant screening in asymptomatic patients. [cite:Harrison 21e Ch 297]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.